Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
AB7341kf51RdyNsF
